Nicola Redfern has been promoted from within bluebird bio to become general manager for the company’s UK organisation. Redfern joined bluebird as director of access and value evidence strategy for the UK in 2017.
Before joining bluebird, Redfern had acquired experience at large pharma companies, having previously worked for MSD (known as Merck in North America), Pierre Fabre, Sanofi, Novartis, Celgene and Baxalta, before beginning at bluebird.
Redfern worked at Celgene for close to four years as its director of market access for the UK before then moving onto Baxalta as director of oncology patient access in the UK. After the latter company merged with Shire, she joined bluebird bio.
Andrew Obenshain, bluebird bio’s head of Europe, commented: “Nicola’s new role, which coincides with the opening of our new office in Basingstoke, is part of our wider strategy to expand our European leadership team as we prepare to launch our gene therapies and transition to a fully integrated discovery, development and commercial company.”